Show simple item record

dc.contributor.authorRodas, Gil
dc.contributor.authorSoler, Robert
dc.contributor.authorBalius, Ramón
dc.contributor.authorAlomar, Xavier
dc.contributor.authorPeirau i Terés, Xavier
dc.contributor.authorAlberca, Mercedes
dc.contributor.authorSánchez, Ana
dc.contributor.authorGarcía Sancho, Javier
dc.contributor.authorRodellar, Clementina
dc.contributor.authorRomero, Antonio
dc.contributor.authorMasci, Lorenzo
dc.contributor.authorOrozco, Lluís
dc.contributor.authorMaffulli, Nicola
dc.date.accessioned2020-11-12T08:05:13Z
dc.date.available2020-11-12T08:05:13Z
dc.date.issued2019
dc.identifier.issn1749-799X
dc.identifier.urihttp://hdl.handle.net/10459.1/69846
dc.description.abstractIntroduction: Patellar tendon overuse injuries are common in athletes. Imaging may show a change in tissue structure with tendon thickening and disruption of the intratendinous substance. We wish to test the hypothesis that both autologous bone marrow expanded mesenchymal stem cells and autologous leukocyte-poor platelet-rich plasma (LP-PRP) implanted into the area of the disrupted tendinopathic patellar tendon will restore function, but tendon regeneration tissue will only be observed in the subjects treated with autologous bone marrow expanded mesenchymal stem cells. Methods and analysis: This is a single-centre, pilot phase I/II, double-blinded clinical trial with randomisation with active control. Twenty patients with a diagnosis of patellar tendinopathy with imaging changes (tendon thickening and disruption of the intratendinous substance at the proximal portion of the patellar tendon) will be randomised in a 1:1 ratio to receive a local injection of either bone-marrow autologous mesenchymal stem cells (MSC), isolated and cultured under GMP at The Institute of Biology and Molecular Genetics (IBGM) (Spain) or P-PRP. The study will have two aims: first, to ascertain whether a clinically relevant improvement after 3, 6 and 12 months according to the visual analogue scale (VAS), Victorian Institute of Sport Assessment for patellar tendons (VISA-P) and dynamometry scales (DYN) will be achieved; and second, to ascertain whether the proposed intervention will restore tendon structure as determined by ultrasonography (US), Doppler ultrasonography (DUS), and innovative MRI and ultrasound techniques: Magnetic Resonance T2 FAT SAT (UTE, Ultrashort Echo TE) sequence and Ultrasound Tissue Characterization (UTC). Patients who are randomised to the P-PRP treatment group but do not achieve a satisfactory primary endpoint after 6 months will be offered treatment with MSC.ca_ES
dc.language.isoengca_ES
dc.publisherSpringer Natureca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1186/s13018-019-1477-2ca_ES
dc.relation.ispartofJournal of Orthopaedic Surgery and Research, 2019, vol. 14, article441ca_ES
dc.rightscc-by (c) Rodas et al., 2019ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectTendinopathyca_ES
dc.subjectMesenchymal stem cellsca_ES
dc.subjectPlatelet-rich plasmaca_ES
dc.titleAutologous bone marrow expanded mesenchymal stem cells in patellar tendinopathy: protocol for a phase I/II, single-centre, randomized with active control PRP, double-blinded clinical trialca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.identifier.idgrec029890
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1186/s13018-019-1477-2


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by (c) Rodas et al., 2019
Except where otherwise noted, this item's license is described as cc-by (c) Rodas et al., 2019